Visualization of dopamine D1, D2 and D3 receptor mRNA's in human and rat brain
Identifieur interne : 000A42 ( Istex/Corpus ); précédent : 000A41; suivant : 000A43Visualization of dopamine D1, D2 and D3 receptor mRNA's in human and rat brain
Auteurs : G Mengod ; M Villar ; G Landwehrmeyer ; M Martinez ; H Niznik ; R Sunahara ; P Seeman ; B O ; A Probst ; J PalaciosSource :
- Neurochemistry International [ 0197-0186 ] ; 1992.
Abstract
Using 32P-labelled oligonucleotides derived from the coding regions of dopamine D1, D2 and D3 receptor mRNAs we localized cells containing transcripts for these receptors in the human (hD1, hD2) and rat brain (rD1, rD2, rD3). Dopamine D1 receptor mRNA was detected at high levels in neurons of the caudate and putamen as well as in the nucleus accumbens in both human and rat brain. In the rat brain D1 receptor mRNA was also abundant in the olfactory tubercles and several thalamic nuclei. In both species D1 mRNA was absent from the neurons of the substantia nigra and the ventral tegmental area as well as from the globus pallidus medialis in humans and entopeduncular nucleus in rats. In contrast, dopamine D2 receptor mRNA was found in dopaminergic neurons of the substantia nigra pars compacta and of the ventral tegmental area. In addition high levels of D2 mRNA were detected in neurons of the caudate, putamen and accumbens nuclei, the olfactory tubercle and the anterior lobe of pituitary gland. In the rat the highest level of hybridization was found in the intermediate lobe of the pituitary gland. In the rat brain dopamine D3 mRNA was mainly detected in the Islands of Calleja and at lower levels in the anterior nucleus accumbens, the medial mammillary nucleus as well as in the bed nucleus of the stria terminalis. In general, a good agreement was found between the distribution of transcripts and binding sites labelled with the D1 antagonist SCH 23390 or with the D2 ligand SDZ 205–502. For D1 receptors, the main exceptions were the absence of mRNA in the globus pallidus and the substantia nigra despite the high densities of binding sites in these regions. For D2 receptors, regions where binding sites but not mRNA were detected include the olfactory bulb, neocortex, hippocampus and superior colliculus.
Url:
DOI: 10.1016/0197-0186(92)90208-9
Links to Exploration step
ISTEX:4065D2E6B61EE38DD11F5C3D134879C31DA85867Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Visualization of dopamine D1, D2 and D3 receptor mRNA's in human and rat brain</title><author><name sortKey="Mengod, G" sort="Mengod, G" uniqKey="Mengod G" first="G" last="Mengod">G Mengod</name><affiliation><mods:affiliation>Preclinical Research, Sandoz Pharma Ltd, 4002 Basel, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="Villar, M T" sort="Villar, M T" uniqKey="Villar M" first="M" last="Villar">M Villar</name><affiliation><mods:affiliation>Preclinical Research, Sandoz Pharma Ltd, 4002 Basel, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="Landwehrmeyer, G B" sort="Landwehrmeyer, G B" uniqKey="Landwehrmeyer G" first="G" last="Landwehrmeyer">G Landwehrmeyer</name><affiliation><mods:affiliation>Institute of Pathology, University of Basel, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="Martinez Mir, M I" sort="Martinez Mir, M I" uniqKey="Martinez Mir M" first="M" last="Martinez">M Martinez</name><affiliation><mods:affiliation>Preclinical Research, Sandoz Pharma Ltd, 4002 Basel, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="Niznik, H B" sort="Niznik, H B" uniqKey="Niznik H" first="H" last="Niznik">H Niznik</name><affiliation><mods:affiliation>Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Sunahara, R K" sort="Sunahara, R K" uniqKey="Sunahara R" first="R" last="Sunahara">R Sunahara</name><affiliation><mods:affiliation>Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Seeman, P" sort="Seeman, P" uniqKey="Seeman P" first="P" last="Seeman">P Seeman</name><affiliation><mods:affiliation>Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="O Dowd, B F" sort="O Dowd, B F" uniqKey="O Dowd B" first="B" last="O">B O</name><affiliation><mods:affiliation>Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Probst, A" sort="Probst, A" uniqKey="Probst A" first="A" last="Probst">A Probst</name><affiliation><mods:affiliation>Institute of Pathology, University of Basel, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="Palacios, J M" sort="Palacios, J M" uniqKey="Palacios J" first="J" last="Palacios">J Palacios</name><affiliation><mods:affiliation>Preclinical Research, Sandoz Pharma Ltd, 4002 Basel, Switzerland</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4065D2E6B61EE38DD11F5C3D134879C31DA85867</idno><date when="1992" year="1992">1992</date><idno type="doi">10.1016/0197-0186(92)90208-9</idno><idno type="url">https://api.istex.fr/document/4065D2E6B61EE38DD11F5C3D134879C31DA85867/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000A42</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Visualization of dopamine D1, D2 and D3 receptor mRNA's in human and rat brain</title><author><name sortKey="Mengod, G" sort="Mengod, G" uniqKey="Mengod G" first="G" last="Mengod">G Mengod</name><affiliation><mods:affiliation>Preclinical Research, Sandoz Pharma Ltd, 4002 Basel, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="Villar, M T" sort="Villar, M T" uniqKey="Villar M" first="M" last="Villar">M Villar</name><affiliation><mods:affiliation>Preclinical Research, Sandoz Pharma Ltd, 4002 Basel, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="Landwehrmeyer, G B" sort="Landwehrmeyer, G B" uniqKey="Landwehrmeyer G" first="G" last="Landwehrmeyer">G Landwehrmeyer</name><affiliation><mods:affiliation>Institute of Pathology, University of Basel, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="Martinez Mir, M I" sort="Martinez Mir, M I" uniqKey="Martinez Mir M" first="M" last="Martinez">M Martinez</name><affiliation><mods:affiliation>Preclinical Research, Sandoz Pharma Ltd, 4002 Basel, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="Niznik, H B" sort="Niznik, H B" uniqKey="Niznik H" first="H" last="Niznik">H Niznik</name><affiliation><mods:affiliation>Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Sunahara, R K" sort="Sunahara, R K" uniqKey="Sunahara R" first="R" last="Sunahara">R Sunahara</name><affiliation><mods:affiliation>Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Seeman, P" sort="Seeman, P" uniqKey="Seeman P" first="P" last="Seeman">P Seeman</name><affiliation><mods:affiliation>Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="O Dowd, B F" sort="O Dowd, B F" uniqKey="O Dowd B" first="B" last="O">B O</name><affiliation><mods:affiliation>Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Probst, A" sort="Probst, A" uniqKey="Probst A" first="A" last="Probst">A Probst</name><affiliation><mods:affiliation>Institute of Pathology, University of Basel, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="Palacios, J M" sort="Palacios, J M" uniqKey="Palacios J" first="J" last="Palacios">J Palacios</name><affiliation><mods:affiliation>Preclinical Research, Sandoz Pharma Ltd, 4002 Basel, Switzerland</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Neurochemistry International</title><title level="j" type="abbrev">NCI</title><idno type="ISSN">0197-0186</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1992">1992</date><biblScope unit="volume">20</biblScope><biblScope unit="supplement">S</biblScope><biblScope unit="page" from="33">33</biblScope><biblScope unit="page" to="43">43</biblScope></imprint><idno type="ISSN">0197-0186</idno></series><idno type="istex">4065D2E6B61EE38DD11F5C3D134879C31DA85867</idno><idno type="DOI">10.1016/0197-0186(92)90208-9</idno><idno type="PII">0197-0186(92)90208-9</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0197-0186</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Using 32P-labelled oligonucleotides derived from the coding regions of dopamine D1, D2 and D3 receptor mRNAs we localized cells containing transcripts for these receptors in the human (hD1, hD2) and rat brain (rD1, rD2, rD3). Dopamine D1 receptor mRNA was detected at high levels in neurons of the caudate and putamen as well as in the nucleus accumbens in both human and rat brain. In the rat brain D1 receptor mRNA was also abundant in the olfactory tubercles and several thalamic nuclei. In both species D1 mRNA was absent from the neurons of the substantia nigra and the ventral tegmental area as well as from the globus pallidus medialis in humans and entopeduncular nucleus in rats. In contrast, dopamine D2 receptor mRNA was found in dopaminergic neurons of the substantia nigra pars compacta and of the ventral tegmental area. In addition high levels of D2 mRNA were detected in neurons of the caudate, putamen and accumbens nuclei, the olfactory tubercle and the anterior lobe of pituitary gland. In the rat the highest level of hybridization was found in the intermediate lobe of the pituitary gland. In the rat brain dopamine D3 mRNA was mainly detected in the Islands of Calleja and at lower levels in the anterior nucleus accumbens, the medial mammillary nucleus as well as in the bed nucleus of the stria terminalis. In general, a good agreement was found between the distribution of transcripts and binding sites labelled with the D1 antagonist SCH 23390 or with the D2 ligand SDZ 205–502. For D1 receptors, the main exceptions were the absence of mRNA in the globus pallidus and the substantia nigra despite the high densities of binding sites in these regions. For D2 receptors, regions where binding sites but not mRNA were detected include the olfactory bulb, neocortex, hippocampus and superior colliculus.</div></front></TEI><istex><corpusName>elsevier</corpusName><author><json:item><name>G. Mengod</name><affiliations><json:string>Preclinical Research, Sandoz Pharma Ltd, 4002 Basel, Switzerland</json:string></affiliations></json:item><json:item><name>M.T. Villaró</name><affiliations><json:string>Preclinical Research, Sandoz Pharma Ltd, 4002 Basel, Switzerland</json:string></affiliations></json:item><json:item><name>G.B. Landwehrmeyer</name><affiliations><json:string>Institute of Pathology, University of Basel, Switzerland</json:string></affiliations></json:item><json:item><name>M.I. Martinez-Mir</name><affiliations><json:string>Preclinical Research, Sandoz Pharma Ltd, 4002 Basel, Switzerland</json:string></affiliations></json:item><json:item><name>H.B. Niznik</name><affiliations><json:string>Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada</json:string></affiliations></json:item><json:item><name>R.K. Sunahara</name><affiliations><json:string>Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada</json:string></affiliations></json:item><json:item><name>P. Seeman</name><affiliations><json:string>Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada</json:string></affiliations></json:item><json:item><name>B.F. O'Dowd</name><affiliations><json:string>Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada</json:string></affiliations></json:item><json:item><name>A. Probst</name><affiliations><json:string>Institute of Pathology, University of Basel, Switzerland</json:string></affiliations></json:item><json:item><name>J.M. Palacios</name><affiliations><json:string>Preclinical Research, Sandoz Pharma Ltd, 4002 Basel, Switzerland</json:string></affiliations></json:item></author><language><json:string>eng</json:string></language><abstract>Using 32P-labelled oligonucleotides derived from the coding regions of dopamine D1, D2 and D3 receptor mRNAs we localized cells containing transcripts for these receptors in the human (hD1, hD2) and rat brain (rD1, rD2, rD3). Dopamine D1 receptor mRNA was detected at high levels in neurons of the caudate and putamen as well as in the nucleus accumbens in both human and rat brain. In the rat brain D1 receptor mRNA was also abundant in the olfactory tubercles and several thalamic nuclei. In both species D1 mRNA was absent from the neurons of the substantia nigra and the ventral tegmental area as well as from the globus pallidus medialis in humans and entopeduncular nucleus in rats. In contrast, dopamine D2 receptor mRNA was found in dopaminergic neurons of the substantia nigra pars compacta and of the ventral tegmental area. In addition high levels of D2 mRNA were detected in neurons of the caudate, putamen and accumbens nuclei, the olfactory tubercle and the anterior lobe of pituitary gland. In the rat the highest level of hybridization was found in the intermediate lobe of the pituitary gland. In the rat brain dopamine D3 mRNA was mainly detected in the Islands of Calleja and at lower levels in the anterior nucleus accumbens, the medial mammillary nucleus as well as in the bed nucleus of the stria terminalis. In general, a good agreement was found between the distribution of transcripts and binding sites labelled with the D1 antagonist SCH 23390 or with the D2 ligand SDZ 205–502. For D1 receptors, the main exceptions were the absence of mRNA in the globus pallidus and the substantia nigra despite the high densities of binding sites in these regions. For D2 receptors, regions where binding sites but not mRNA were detected include the olfactory bulb, neocortex, hippocampus and superior colliculus.</abstract><qualityIndicators><score>7.856</score><pdfVersion>1.2</pdfVersion><pdfPageSize>540 x 713 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1826</abstractCharCount><pdfWordCount>4856</pdfWordCount><pdfCharCount>29110</pdfCharCount><pdfPageCount>11</pdfPageCount><abstractWordCount>303</abstractWordCount></qualityIndicators><title>Visualization of dopamine D1, D2 and D3 receptor mRNA's in human and rat brain</title><pii><json:string>0197-0186(92)90208-9</json:string></pii><genre><json:string>research-article</json:string></genre><serie><volume>86</volume><pages><last>9766</last><first>9762</first></pages><genre><json:string>Book</json:string></genre><language><json:string>unknown</json:string></language><title>Proc. Natl. Acad. Sci. USA</title></serie><host><volume>20</volume><pii><json:string>S0197-0186(00)X0206-9</json:string></pii><editor><json:item><name>Pierfranco Spano</name></json:item><json:item><name>Geoffrey N. Woodruff</name></json:item><json:item><name>Gian Luigi Gessa</name></json:item></editor><pages><last>43</last><first>33</first></pages><conference><json:item><name>Satellite Meeting of the XIth International Congress of Pharmacology , Villa Olmo, Como, Italy 19900708 19900711</name></json:item></conference><issn><json:string>0197-0186</json:string></issn><genre></genre><language><json:string>unknown</json:string></language><title>Neurochemistry International</title><publicationDate>1992</publicationDate></host><categories><wos><json:string>BIOCHEMISTRY & MOLECULAR BIOLOGY</json:string><json:string>NEUROSCIENCES</json:string></wos></categories><publicationDate>1992</publicationDate><copyrightDate>1992</copyrightDate><doi><json:string>10.1016/0197-0186(92)90208-9</json:string></doi><id>4065D2E6B61EE38DD11F5C3D134879C31DA85867</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/4065D2E6B61EE38DD11F5C3D134879C31DA85867/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/4065D2E6B61EE38DD11F5C3D134879C31DA85867/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/4065D2E6B61EE38DD11F5C3D134879C31DA85867/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">Visualization of dopamine D1, D2 and D3 receptor mRNA's in human and rat brain</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><date>1992</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Visualization of dopamine D1, D2 and D3 receptor mRNA's in human and rat brain</title><author><persName><forename type="first">G.</forename><surname>Mengod</surname></persName><affiliation>Author to whom all correspondence should be addressed.</affiliation><affiliation>Preclinical Research, Sandoz Pharma Ltd, 4002 Basel, Switzerland</affiliation></author><author><persName><forename type="first">M.T.</forename><surname>Villaró</surname></persName><affiliation>Preclinical Research, Sandoz Pharma Ltd, 4002 Basel, Switzerland</affiliation></author><author><persName><forename type="first">G.B.</forename><surname>Landwehrmeyer</surname></persName><affiliation>Institute of Pathology, University of Basel, Switzerland</affiliation></author><author><persName><forename type="first">M.I.</forename><surname>Martinez-Mir</surname></persName><affiliation>Preclinical Research, Sandoz Pharma Ltd, 4002 Basel, Switzerland</affiliation></author><author><persName><forename type="first">H.B.</forename><surname>Niznik</surname></persName><affiliation>Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada</affiliation></author><author><persName><forename type="first">R.K.</forename><surname>Sunahara</surname></persName><affiliation>Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada</affiliation></author><author><persName><forename type="first">P.</forename><surname>Seeman</surname></persName><affiliation>Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada</affiliation></author><author><persName><forename type="first">B.F.</forename><surname>O'Dowd</surname></persName><affiliation>Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada</affiliation></author><author><persName><forename type="first">A.</forename><surname>Probst</surname></persName><affiliation>Institute of Pathology, University of Basel, Switzerland</affiliation></author><author><persName><forename type="first">J.M.</forename><surname>Palacios</surname></persName><affiliation>Preclinical Research, Sandoz Pharma Ltd, 4002 Basel, Switzerland</affiliation></author></analytic><monogr><title level="j">Neurochemistry International</title><title level="j" type="abbrev">NCI</title><idno type="pISSN">0197-0186</idno><idno type="PII">S0197-0186(00)X0206-9</idno><meeting><addName>Satellite Meeting of the XIth International Congress of Pharmacology , Villa Olmo, Como, Italy</addName><date>19900708</date><date>19900711</date></meeting><editor><persName>Pierfranco Spano</persName></editor><editor><persName>Geoffrey N. Woodruff</persName></editor><editor><persName>Gian Luigi Gessa</persName></editor><imprint><publisher>ELSEVIER</publisher><date type="published" when="1992"></date><biblScope unit="volume">20</biblScope><biblScope unit="supplement">S</biblScope><biblScope unit="page" from="33">33</biblScope><biblScope unit="page" to="43">43</biblScope></imprint></monogr><idno type="istex">4065D2E6B61EE38DD11F5C3D134879C31DA85867</idno><idno type="DOI">10.1016/0197-0186(92)90208-9</idno><idno type="PII">0197-0186(92)90208-9</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1992</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Using 32P-labelled oligonucleotides derived from the coding regions of dopamine D1, D2 and D3 receptor mRNAs we localized cells containing transcripts for these receptors in the human (hD1, hD2) and rat brain (rD1, rD2, rD3). Dopamine D1 receptor mRNA was detected at high levels in neurons of the caudate and putamen as well as in the nucleus accumbens in both human and rat brain. In the rat brain D1 receptor mRNA was also abundant in the olfactory tubercles and several thalamic nuclei. In both species D1 mRNA was absent from the neurons of the substantia nigra and the ventral tegmental area as well as from the globus pallidus medialis in humans and entopeduncular nucleus in rats. In contrast, dopamine D2 receptor mRNA was found in dopaminergic neurons of the substantia nigra pars compacta and of the ventral tegmental area. In addition high levels of D2 mRNA were detected in neurons of the caudate, putamen and accumbens nuclei, the olfactory tubercle and the anterior lobe of pituitary gland. In the rat the highest level of hybridization was found in the intermediate lobe of the pituitary gland. In the rat brain dopamine D3 mRNA was mainly detected in the Islands of Calleja and at lower levels in the anterior nucleus accumbens, the medial mammillary nucleus as well as in the bed nucleus of the stria terminalis. In general, a good agreement was found between the distribution of transcripts and binding sites labelled with the D1 antagonist SCH 23390 or with the D2 ligand SDZ 205–502. For D1 receptors, the main exceptions were the absence of mRNA in the globus pallidus and the substantia nigra despite the high densities of binding sites in these regions. For D2 receptors, regions where binding sites but not mRNA were detected include the olfactory bulb, neocortex, hippocampus and superior colliculus.</p></abstract></profileDesc><revisionDesc><change when="1992">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/4065D2E6B61EE38DD11F5C3D134879C31DA85867/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>NCI</jid><aid>92902089</aid><ce:pii>0197-0186(92)90208-9</ce:pii><ce:doi>10.1016/0197-0186(92)90208-9</ce:doi><ce:copyright type="unknown" year="1992"></ce:copyright></item-info><head><ce:title>Visualization of dopamine D<ce:inf>1</ce:inf>, D<ce:inf>2</ce:inf> and D<ce:inf>3</ce:inf> receptor mRNA's in human and rat brain</ce:title><ce:author-group><ce:author><ce:given-name>G.</ce:given-name><ce:surname>Mengod</ce:surname><ce:cross-ref refid="COR1"><ce:sup>∗</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF1"><ce:sup>1</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>M.T.</ce:given-name><ce:surname>Villaró</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>1</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>G.B.</ce:given-name><ce:surname>Landwehrmeyer</ce:surname><ce:cross-ref refid="AFF2"><ce:sup>2</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>M.I.</ce:given-name><ce:surname>Martinez-Mir</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>1</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>H.B.</ce:given-name><ce:surname>Niznik</ce:surname><ce:cross-ref refid="AFF3"><ce:sup>3</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF4"><ce:sup>4</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>R.K.</ce:given-name><ce:surname>Sunahara</ce:surname><ce:cross-ref refid="AFF3"><ce:sup>3</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>P.</ce:given-name><ce:surname>Seeman</ce:surname><ce:cross-ref refid="AFF3"><ce:sup>3</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF4"><ce:sup>4</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>B.F.</ce:given-name><ce:surname>O'Dowd</ce:surname><ce:cross-ref refid="AFF3"><ce:sup>3</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF4"><ce:sup>4</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>A.</ce:given-name><ce:surname>Probst</ce:surname><ce:cross-ref refid="AFF2"><ce:sup>2</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>J.M.</ce:given-name><ce:surname>Palacios</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>1</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="AFF1"><ce:label>1</ce:label><ce:textfn>Preclinical Research, Sandoz Pharma Ltd, 4002 Basel, Switzerland</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>2</ce:label><ce:textfn>Institute of Pathology, University of Basel, Switzerland</ce:textfn></ce:affiliation><ce:affiliation id="AFF3"><ce:label>3</ce:label><ce:textfn>Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada</ce:textfn></ce:affiliation><ce:affiliation id="AFF4"><ce:label>4</ce:label><ce:textfn>Addiction Research Foundation, 33 Russell Street, Toronto, Ontario, Canada</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>∗</ce:label><ce:text>Author to whom all correspondence should be addressed.</ce:text></ce:correspondence></ce:author-group><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>Using <ce:sup loc="pre">32</ce:sup>P-labelled oligonucleotides derived from the coding regions of dopamine D<ce:inf>1</ce:inf>, D<ce:inf>2</ce:inf> and D<ce:inf>3</ce:inf> receptor mRNAs we localized cells containing transcripts for these receptors in the human (hD<ce:inf>1</ce:inf>, hD<ce:inf>2</ce:inf>) and rat brain (rD<ce:inf>1</ce:inf>, rD<ce:inf>2</ce:inf>, rD<ce:inf>3</ce:inf>). Dopamine D<ce:inf>1</ce:inf> receptor mRNA was detected at high levels in neurons of the caudate and putamen as well as in the nucleus accumbens in both human and rat brain. In the rat brain D<ce:inf>1</ce:inf> receptor mRNA was also abundant in the olfactory tubercles and several thalamic nuclei. In both species D<ce:inf>1</ce:inf> mRNA was absent from the neurons of the substantia nigra and the ventral tegmental area as well as from the globus pallidus medialis in humans and entopeduncular nucleus in rats. In contrast, dopamine D<ce:inf>2</ce:inf> receptor mRNA was found in dopaminergic neurons of the substantia nigra pars compacta and of the ventral tegmental area. In addition high levels of D<ce:inf>2</ce:inf> mRNA were detected in neurons of the caudate, putamen and accumbens nuclei, the olfactory tubercle and the anterior lobe of pituitary gland. In the rat the highest level of hybridization was found in the intermediate lobe of the pituitary gland. In the rat brain dopamine D<ce:inf>3</ce:inf> mRNA was mainly detected in the Islands of Calleja and at lower levels in the anterior nucleus accumbens, the medial mammillary nucleus as well as in the bed nucleus of the stria terminalis. In general, a good agreement was found between the distribution of transcripts and binding sites labelled with the D<ce:inf>1</ce:inf> antagonist SCH 23390 or with the D<ce:inf>2</ce:inf> ligand SDZ 205–502. For D<ce:inf>1</ce:inf> receptors, the main exceptions were the absence of mRNA in the globus pallidus and the substantia nigra despite the high densities of binding sites in these regions. For D<ce:inf>2</ce:inf> receptors, regions where binding sites but not mRNA were detected include the olfactory bulb, neocortex, hippocampus and superior colliculus.</ce:simple-para></ce:abstract-sec></ce:abstract></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Visualization of dopamine D1, D2 and D3 receptor mRNA's in human and rat brain</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Visualization of dopamine D</title></titleInfo><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Mengod</namePart><affiliation>Preclinical Research, Sandoz Pharma Ltd, 4002 Basel, Switzerland</affiliation><description>Author to whom all correspondence should be addressed.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.T.</namePart><namePart type="family">Villaró</namePart><affiliation>Preclinical Research, Sandoz Pharma Ltd, 4002 Basel, Switzerland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.B.</namePart><namePart type="family">Landwehrmeyer</namePart><affiliation>Institute of Pathology, University of Basel, Switzerland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.I.</namePart><namePart type="family">Martinez-Mir</namePart><affiliation>Preclinical Research, Sandoz Pharma Ltd, 4002 Basel, Switzerland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.B.</namePart><namePart type="family">Niznik</namePart><affiliation>Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.K.</namePart><namePart type="family">Sunahara</namePart><affiliation>Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">Seeman</namePart><affiliation>Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.F.</namePart><namePart type="family">O'Dowd</namePart><affiliation>Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Probst</namePart><affiliation>Institute of Pathology, University of Basel, Switzerland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.M.</namePart><namePart type="family">Palacios</namePart><affiliation>Preclinical Research, Sandoz Pharma Ltd, 4002 Basel, Switzerland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article">Full-length article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1992</dateIssued><copyrightDate encoding="w3cdtf">1992</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Using 32P-labelled oligonucleotides derived from the coding regions of dopamine D1, D2 and D3 receptor mRNAs we localized cells containing transcripts for these receptors in the human (hD1, hD2) and rat brain (rD1, rD2, rD3). Dopamine D1 receptor mRNA was detected at high levels in neurons of the caudate and putamen as well as in the nucleus accumbens in both human and rat brain. In the rat brain D1 receptor mRNA was also abundant in the olfactory tubercles and several thalamic nuclei. In both species D1 mRNA was absent from the neurons of the substantia nigra and the ventral tegmental area as well as from the globus pallidus medialis in humans and entopeduncular nucleus in rats. In contrast, dopamine D2 receptor mRNA was found in dopaminergic neurons of the substantia nigra pars compacta and of the ventral tegmental area. In addition high levels of D2 mRNA were detected in neurons of the caudate, putamen and accumbens nuclei, the olfactory tubercle and the anterior lobe of pituitary gland. In the rat the highest level of hybridization was found in the intermediate lobe of the pituitary gland. In the rat brain dopamine D3 mRNA was mainly detected in the Islands of Calleja and at lower levels in the anterior nucleus accumbens, the medial mammillary nucleus as well as in the bed nucleus of the stria terminalis. In general, a good agreement was found between the distribution of transcripts and binding sites labelled with the D1 antagonist SCH 23390 or with the D2 ligand SDZ 205–502. For D1 receptors, the main exceptions were the absence of mRNA in the globus pallidus and the substantia nigra despite the high densities of binding sites in these regions. For D2 receptors, regions where binding sites but not mRNA were detected include the olfactory bulb, neocortex, hippocampus and superior colliculus.</abstract><relatedItem type="host"><titleInfo><title>Neurochemistry International</title></titleInfo><titleInfo type="abbreviated"><title>NCI</title></titleInfo><name type="conference"><namePart>Satellite Meeting of the XIth International Congress of Pharmacology , Villa Olmo, Como, Italy</namePart><namePart type="date">19900708</namePart><namePart type="date" encoding="w3cdtf">19900711</namePart></name><name type="personal"><namePart>Pierfranco Spano</namePart><role><roleTerm type="text">editor</roleTerm></role></name><name type="personal"><namePart>Geoffrey N. Woodruff</namePart><role><roleTerm type="text">editor</roleTerm></role></name><name type="personal"><namePart>Gian Luigi Gessa</namePart><role><roleTerm type="text">editor</roleTerm></role></name><originInfo><dateIssued encoding="w3cdtf">199203</dateIssued></originInfo><identifier type="ISSN">0197-0186</identifier><identifier type="PII">S0197-0186(00)X0206-9</identifier><part><date>199203</date><detail type="issue"><title>Satellite Meeting of the XIth International Congress of Pharmacology , Villa Olmo, Como, Italy</title></detail><detail type="volume"><number>20</number><caption>vol.</caption></detail><detail type="supplement"><number>S</number><caption>Suppl.</caption></detail><extent unit="issue pages"><start>1</start><end>343</end></extent><extent unit="pages"><start>33</start><end>43</end></extent></part></relatedItem><identifier type="istex">4065D2E6B61EE38DD11F5C3D134879C31DA85867</identifier><identifier type="DOI">10.1016/0197-0186(92)90208-9</identifier><identifier type="PII">0197-0186(92)90208-9</identifier><recordInfo><recordOrigin>ELSEVIER</recordOrigin></recordInfo></mods></metadata><enrichments><istex:catWosTEI uri="https://api.istex.fr/document/4065D2E6B61EE38DD11F5C3D134879C31DA85867/enrichments/catWos"><teiHeader><profileDesc><textClass><classCode scheme="WOS">BIOCHEMISTRY & MOLECULAR BIOLOGY</classCode><classCode scheme="WOS">NEUROSCIENCES</classCode></textClass></profileDesc></teiHeader></istex:catWosTEI></enrichments></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A42 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000A42 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:4065D2E6B61EE38DD11F5C3D134879C31DA85867
|texte= Visualization of dopamine D1, D2 and D3 receptor mRNA's in human and rat brain
}}
| This area was generated with Dilib version V0.6.19. |  |